Webinar
Scientific Meeting
THE EVOLVING LANDSCAPE IN THE TREATMENT OF MS: IS THERE STILL A ROLE FOR INJECTABLE THERAPIES?
Jetzt online ansehen
Vortrag Prof. Mark Freedman “The current and future therapeutic management of multiple sclerosis”
Sie müssen sich als Arzt authentifizieren
bevor Sie den erweiterten Inhalt dieser Seite sehen können.
Ihre Daten werden auf Korrektheit überprüft.
Dr. Mark Freedman
Dr. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus and a Senior Scientist at the Ottawa Hospital Research Institute. A graduate of the University of Toronto, Dr. Freedman holds his Masters Degree in Molecular Neurochemistry and continued his postgraduate work specializing in neurology and neuroimmunology.
His specialized training took him to the Weizmann Institute of Science, Israel ; The National Hospital, Queen Square, London UK, as well as the Montreal Neurological Institute, where he subsequently joined the clinical staff at McGill as an Assistant Professor. He holds his specialist certi cation in Quebec CSPQ and all of Canada FRCP(C) and is a Fellow of both the American Neurological Association (FANA) and the American Academy of Neurology (FAAN).
Dr. Freedman has published nearly 300 pieces, including articles, books, book chapters and abstracts and has been invited to give hundreds of lectures and presentations nationally and internationally. His extensive research includes the area of molecular neurochemistry, cellular immunology, neuroimmunology and clinical research studies in MS. He is currently holding peer reviewed and industry related funding for clinical and translational research investigating potential MS treatments with a particular interest in cell based therapies.
He is the lead investigator in the Canadian Bone Marrow Transplant Study in MS and co-leader of the International Mesenchymal Stem Cell Transplantation for MS (MESEMS) Study Group. Dr. Freedman has nearly 30 years of experience in the management of patients with multiple sclerosis and has been the principal investigator on numerous clinical trials with new therapeutic agents for MS. He has experience from serving on several research study steering committees as well as data safety monitoring boards. He serves on the editorial boards for several journals including the Multiple Sclerosis Journal. He has also served on several national and international committees and is currently the Treasurer of the Americas Committee for Treatment and Research in MS (ACTRIMS).